Navigation Links
'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart
Date:7/22/2014

TUCSON, Ariz., July 22, 2014 /PRNewswire/ -- A central New York recipient of a SynCardia temporary Total Artificial Heart implant is home, discharged from University of Rochester's Strong Memorial Hospital with the Freedom® portable driver to wait for a matching donor heart.

Fontana, a 64-year-old retiree from a Syracuse architectural hardware company, suffered from heart disease—cardiomyopathy—for decades. He managed the condition with medications, an implantable defibrillator and a pacemaker.

Recently, the Camillus resident experienced ventricular tachycardia in which his heart would race until the pacemaker fired electrical pulses to normalize its rhythm. His doctors performed a procedure in February 2013 to fix the problem, but the condition returned.

By fall 2013, Fontana's conditioned worsened. "It became apparent quite quickly that we couldn't control it and we had to implant the Total Artificial Heart or he was not going to survive," says Dr. Jeffrey Alexis, Fontana's transplant cardiologist with the hospital's Program in Heart Failure and Transplantation. The implant was performed Sept. 24, 2013.

Like a heart transplant, the SynCardia Total Artificial Heart replaces the diseased heart's two failing ventricles and four heart valves. It is the only FDA, Health Canada and CE approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.

"This gives him time to stabilize, to build his strength up, to be able to walk, to feel stronger," says Alexis.

When Fontana became clinically stable, he was able to go home June 2, 2014 with the 13.5-pound Freedom portable driver, which powers the SynCardia Heart with precisely calibrated pulses of air and vacuum.

At home, Fontana spends time with his five grandkids, goes shopping and exercises on a treadmill.

"This machine, this artificial device is what's keeping me moving," Fontana told The Post-Standard in Syracuse.

Fontana has maintained his humor throughout. "I get a kick out of saying, 'I'm a heartless SOB.' I don't have a heart."

He also credits his wife, Toni, with keeping him motivated to get strong for his heart transplant.

"I'm still here and I'm glad for that," he told the newspaper. "I have a lot of life left to do."

For additional information, please visit: http://www.syncardia.com/
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn
Share and Discover on Google+

SynCardia Systems, Inc. in Tucson, Arizona is the privately-held owner and manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.

More than 1,300 implants of the SynCardia Total Artificial Heart accounts for over 400 patient years of life on the device. Since January 2011 more than 400 SynCardia Hearts have been implanted.

The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 76 years old. The longest a patient has lived with a SynCardia Heart was nearly four years (1,374 days) before receiving a successful donor heart transplant Sept. 11, 2011.

SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to leave the hospital and live at home and in their communities. The wearable Freedom driver has been used by more than 175 patients, accounting for over 100 years of support.

Photo - http://photos.prnewswire.com/prnh/20140722/129134


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
2. Government Affairs & Public Policy Groups Playing Critical Role in Patient Engagement, Reports Best Practices, LLC
3. Genetic And Microbiome Discoveries Point The Way To New Treatments For Crohns & Colitis Patients
4. Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
5. Physicians to Pharmas: Provide Patient Services or Face Irrelevance
6. Simbionixs Innovative Solution for Patient Specific Simulation Receives Further Global Recognition
7. ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes
8. Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
9. Innovative Lösung von Simbionix für patientenspezifische Simulation erhält noch mehr weltweite Anerkennung
10. NxStage Drives to Educate Kidney Patients
11. Mevesi Enhances Population Management Solution with Patient Education Videos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... le 24 février 2017 ITL Limited, ( ASX : ITD ... est ravie d,annoncer les excellents résultats semestriels clos le ... correspondante. Une présentation complète « Résultats et mise à jour ... ici . Faits marquants ... 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... -- This report analyzes the worldwide markets for Chiral Technology ... Products: Intermediates, Analytical, and Others. The End Use markets ... The report provides separate comprehensive analytics for the US, ... , and Rest of World. Annual estimates and forecasts ... a six-year historic analysis is provided for these markets. ...
(Date:2/24/2017)... 2017  The particle counters market is projected ... USD 275.9 million in 2016, at a CAGR ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical ... and growth in manufacturing industries in emerging nations ... particle counters. On the other hand, technical limitations ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... to the 7th Edition of International Social Design Awards. , The 7th ... Designers, System Designers, Governments and Institutions worldwide with realized projects and conceptual works. ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... NuevaCare, a ... as diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important ... Bay Area consumers look for home care close to home, and by having city-specific ...
(Date:2/26/2017)... , ... February 26, 2017 , ... IndustryArchive.Org . ... with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales ... the founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the 10th ... Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on how ... management. , ODH will also have an exhibit booth where attendees may speak to ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure ... a specific LRRK2 mutation, according to a study released today at the 1st ... of a link between pesticides and incidence of sporadic PD through occupational exposure. ...
Breaking Medicine News(10 mins):